Read More Pharma Industry News AL-S Pharma’s AP-101 prolongs survival and delays ventilator use in ALS Phase 2 trial AL-S Pharma’s AP-101 showed survival and biomarker gains in ALS Phase 2 study. Find out what this means as the firm prepares for Phase 3. byVenkateshDecember 7, 2025